Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.59 |
| ▸ | MTTP | P55157 | 11/20 | 0.56 |
| ▸ | APOB | P04114 | 9/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.52 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.52 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.52 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6793291 | 0.91 | PTGS1 (0.56) | PTGS1MTTPAPOBSMN1; SMN2CHRNB2 | |
| SCHEMBL6789828 | 0.90 | PTGS1 (0.58) | PTGS1MTTPAPOBSMN1; SMN2CHRNB2 | |
| SCHEMBL6788109 | 0.88 | MTTP (0.56) | PTGS1MTTPAPOBSMN1; SMN2CHRNB2 | |
| SCHEMBL3729112 | 0.87 | NR1H4 (0.58) | PTGS1MTTPAPOBSMN1; SMN2CHRNB2 | |
| SCHEMBL6791178 | 0.86 | PTGS1 (0.67) | PTGS1MTTPAPOBSMN1; SMN2CHRNB2 | |
| SCHEMBL6793696 | 0.86 | KMT2A (0.66) | PTGS1MTTPAPOBSMN1; SMN2CHRNB2 | |
| SCHEMBL7086952 | 0.86 | PLG (0.53) | PTGS1MTTPAPOBSMN1; SMN2CHRNB2 | |
| SCHEMBL6791890 | 0.86 | MTTP (0.59) | PTGS1MTTPAPOBSMN1; SMN2CHRNB2 | |
| SCHEMBL31393757 | 0.86 | CHRNB2 (0.71) | PTGS1MTTPAPOBSMN1; SMN2CHRNB2 | |
| SCHEMBL6793895 | 0.85 | FFAR1 (0.57) | PTGS1MTTPAPOBSMN1; SMN2CHRNB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040058903-A1 | Benzamide compounds as apo b secretion inhibitors | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-03-25 | — | — | US | disclosed |
| EP-1326835-A1 | BENZAMIDE COMPOUNDS AS APO B SECRETION INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-07-16 | — | — | EP | disclosed |
| WO-2002028835-A1 | BENZAMIDE COMPOUNDS AS APO B SECRETION INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-04-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040058903-A1 | Benzamide compounds as apo b secretion inhibitors | APOB, APOL1, SCARB1 | PTGS1 1382/4885MTTP 363/4885APOB 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.